

What is claimed is:

- Sub
a'*
1. A drug dosage form comprising a compound susceptible to moisture-induced degradation and at least one pharmaceutically acceptable excipient prepared under conditions of low compression.
 2. The drug dosage form of claim 1 comprising a capsule.
 3. The drug dosage form of claim 1 comprising a capsule formed of hydroxypropyl methylcellulose.
 4. The drug dosage form of claim 1 wherein the compound is contained in solid form within a capsule.
 5. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 10,000 psi/g.
 6. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 5,000 psi/g.
 7. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 2,000 psi/g.
 8. The drug dosage form of claim 1 wherein the excipient is hydroxypropyl methylcellulose, carboxymethyl cellulose, microcrystalline cellulose, amorphous silicon dioxide, magnesium stearate, starch, sodium starch glycolate, or a combination thereof.
 9. The drug dosage form of claim 1 wherein the excipient has a residual moisture content of

0060974-101000

less than about 10% by weight.

10. The drug dosage form of claim 1 exhibiting improved stability to moisture-induced degradation of the compound as compared with a tableted form of the compound.
11. The drug dosage form of claim 1 comprising a unit dosage form.
12. A drug dosage form for a compound susceptible to moisture-induced degradation comprising the compound admixed with a substantially non-volatile, pharmaceutically acceptable oil.
13. The drug dosage form of claim 12 wherein the oil is an animal or vegetable oil.
14. The drug dosage form of claim 12 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
15. The drug dosage form of claim 12 wherein the oil is a mineral oil or silicone oil.
16. The drug dosage form of claim 12 wherein the compound - oil admixture is present within a capsule.
17. The drug dosage form of claim 12 wherein the compound - oil admixture is present within a soft shell capsule.
18. The drug dosage form of claim 12 wherein the compound - oil admixture is present within a specially sealed hard-shell capsule.
19. The drug dosage form of claim 12 wherein at least some of the compound - oil admixture

is adsorbed on a pharmaceutically acceptable excipient.

The drug dosage form of claim 12 wherein the excipient admixture adsorbed thereupon is within a capsule.

The drug dosage form of claim 12 wherein the excipient admixture adsorbed thereupon is within a tablet.

A drug dosage form for a compound susceptible to oxidation comprising the drug and a pharmaceutically acceptable substantially non-volatile, pharmaceutically acceptable oil.

The drug dosage form of claim 22 wherein the oil is rapeseed, cottonseed, vitamin E, fish, or tallow-derived.

The drug dosage form of claim 22 wherein the oil is a vegetable oil.

The drug dosage form of claim 22 wherein the drug is present within a capsule.

The drug dosage form of claim 22 wherein the drug is present within a tablet.

A drug dosage form comprising a compound susceptible to oxidation admixed with a first pharmaceutically acceptable oil and a pharmaceutically acceptable excipient admixed with a second pharmaceutically acceptable oil.

20. The drug dosage form of claim 12 wherein the excipient having the compound - oil admixture adsorbed thereupon is within a capsule.
21. The drug dosage form of claim 12 wherein the excipient having the compound - oil admixture adsorbed thereupon is within a tablet.
22. A drug dosage form for a compound susceptible to moisture-induced degradation comprising the drug and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.
23. The drug dosage form of claim 22 wherein the oil is an animal or vegetable oil.
24. The drug dosage form of claim 22 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
25. The drug dosage form of claim 22 wherein the oil is a mineral oil or silicone oil.
26. The drug dosage form of claim 22 wherein the drug and the excipient - oil admixture are present within a capsule.
27. The drug dosage form of claim 22 wherein the drug and the excipient - oil admixture are present within a tablet.
28. A drug dosage form comprising a compound susceptible to moisture-induced degradation admixed with a first pharmaceutically acceptable oil together with a pharmaceutically acceptable excipient admixed with a second pharmaceutically acceptable oil.

29. The drug dosage form of claim 28 wherein the first and the second pharmaceutically acceptable oils are, independently, an animal or vegetable oil.
30. The drug dosage form of claim 28 wherein the first and the second pharmaceutically acceptable oils are, independently, olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
31. The drug dosage form of claim 28 wherein the first and the second pharmaceutically acceptable oils are, independently, a mineral oil or silicone oil.
32. The drug dosage form of claim 28 wherein the compound - oil admixture and the excipient - oil admixture are present within a capsule.
33. The drug dosage form of claim 28 wherein the compound - oil admixture and the excipient - oil admixture are present within a tablet.
34. A drug dosage form comprising a compound susceptible to moisture-induced degradation and at least one pharmaceutically acceptable hydrophobic powder.
35. The drug dosage form of claim 34 wherein the hydrophobic powder is triturated directly with the compound.
36. The drug dosage form of claim 34 wherein the hydrophobic powder is magnesium stearate.
37. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit/dose of the compound which has not been processed

employing high compression.

38. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound admixed with a substantially non-volatile, pharmaceutically acceptable oil.
39. The method of claim 38 wherein the compound - oil admixture is present within a capsule.
40. The method of claim 38 wherein the compound - oil admixture is adsorbed on a pharmaceutically acceptable excipient.
41. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.
42. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound and at least one pharmaceutically acceptable hydrophobic powder.